SCHEMBL4079232

SCHEMBL4079232

Cc1[nH]c(=O)c2cc(Cl)ccc2c1C1CCCN1C

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.40
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
OPRL1 P41146 1/20 0.39
HTR3A P46098 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
CHRM2 P08172 6/20 0.38
CHRM4 P08173 6/20 0.38
CHRM5 P08912 6/20 0.38
CHRM1 P11229 6/20 0.38
CHRM3 P20309 6/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073519 0.85 CCNT1 (0.39) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL4072381 0.83 HTR2A (0.49) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL4073316 0.80 OPRM1 (0.48) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4078373 0.78 OPRM1 (0.47) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4073365 0.75 CYP1A2 (0.47) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4072790 0.75 OPRM1 (0.54) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4070060 0.74 OPRM1 (0.51) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4078132 0.74 PARP1 (0.44) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4072256 0.74 OPRM1 (0.50) PARP1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4072310 0.74 OPRM1 (0.47) PARP1OPRM1OPRD1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885OPRM1 3587/4885OPRD1 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.